Cardiology Group Withdraws ‘Choosing Wisely’ Recommendation

In the end it wasn’t wisdom for the ages. The American College of Cardiology said today that it was withdrawing one of its five recommendations in the “Choosing Wisely” campaign.  In 2012 the ACC recommended that heart attack patients should have only their culprit artery unblocked. It said that patients and caregivers should question whether complete revascularization of all…

Click here to continue reading…

What To Expect At The American College of Cardiology Meeting

The ACC begins this Saturday in Washington, DC. Here’s a preview of some of the most highly-anticipated late-breaking clinical trials. On Saturday morning at the opening session the world will finally learn more about the failure of Symplicity HTN-3, the Medtronic trial of renal denervation…. …  Click here to read the entire post on Forbes.  …

Click here to continue reading…

More Guideline Controversy: Blood Pressure Expert Decries ‘Political Correctness’

Now add “political correctness” to the long list of criticisms directed against the recent publication of new and updated cardiovascular guidelines. One leading hypertension expert writes that the authors of the recent AHA/ACC/CDC Science Advisory on blood pressure control were chosen not for their expertise but for political expediency. … Click here to read the full post on Forbes. Confusion…

Click here to continue reading…

Missing High Blood Pressure Guideline Turns Up In JAMA

After  years of delay and many twists and turns, the hypertension guideline originally commissioned by the NIH has now finally been published in JAMA. The evidence-based document contains a major revision of hypertension treatment targets and includes new and somewhat simplified recommendations for drug treatment. The previous US hypertension guideline was published more than a decade ago….

Click here to continue reading…

Controversy Erupts Over Accuracy Of Cardiovascular Risk Calculator For Guidelines

In the face of a highly critical story in the New York Times by Gina Kolata about the new cardiovascular guidelines, authors of the guidelines and leaders of the American Heart Association and the American College of Cardiology defended the value and integrity of the guidelines. The Times story claims that the cardiovascular risk calculator used to assess individual risk in the new guidelines is deeply flawed. “In…

Click here to continue reading…

The Fate Of New Cholesterol Drugs Depends On IMPROVE-IT

Prospects for the highly anticipated new class of cholesterol-lowering drugs, the PCSK9 inhibitors, took a wild roller coaster ride this week. The publication of new lipid guidelines by the American Heart Association and the American College of Cardiology led many observers to think that the promising new drugs under development by Regeneron (in partnership with Sanofi),…

Click here to continue reading…

After Long Wait, Updated US Cardiovascular Guidelines Now Emphasize Risk Instead Of Targets

Original illustration by Max Husten

Updated cardiovascular health guidelines were released today by  the American Heart Association (AHA) and the American College of Cardiology (ACC). The guidelines are designed to provide primary care physicians with evidence-based expert guidance on cholesterol, obesity, risk assessment, and healthy lifestyle. The new guidelines reinforce many of the same messages from previous guidelines, but also…

Click here to continue reading…

Former ACC CEO Takes Reins Of Cardiovascular Research Foundation

The Cardiovascular Research Foundation (CRF) announced today that it had appointed Jack Lewin as its next President and Chief Executive Officer. Lewin is the former CEO of the American College of Cardiology. In April 2012 the ACC announced his abrupt departure from the college. No explanation was ever given for the sudden change. … Click here to read the full…

Click here to continue reading…

Both Overuse And Underuse Explain Disparities In Heart Procedures

A new study finds that groups who have often been found to receive less medical care– non-whites, women, and people without private insurance or who are from urban and rural areas– are less likely to undergo coronary revascularization. But the same study finds that this disparity may be in no small part due to the fact…

Click here to continue reading…

Fuster To Succeed DeMaria As Editor Of JACC

The American College of Cardiology has announced that Valentin Fuster will be the next editor-in-chief of the Journal of the American College of Cardiology. Fuster will succeed the current editor, Anthony DeMaria, beginning in 2014. … Click here to read the full post on Forbes.  …

Click here to continue reading…

Observational Study Lends Support to CRT Guidelines

A large observational study published in JAMA suggests that patients with left bundle-branch block (LBBB) and longer QRS duration derive the most benefit from a cardiac resynchronization therapy defibrillator (CRT-D). The findings appear to support current, but often criticized, guidelines from the American College of Cardiology, American Heart Association, and the Heart Rhythm Society, in which a class I recommendation…

Click here to continue reading…

The Guidelines Are Dead. Long Live The Guidelines.

Following last month’s surprising announcement that the National Heart, Lung, and Blood Institute would no longer issue guidelines, leaders of the American Heart Association and the American College of Cardiology have now announced that are “officially assuming the joint governance, management and public distribution” of the enormously influential cardiovascular prevention guidelines, including the much-delayed and much-anticipated hypertension and cholesterol guidelines (formerly…

Click here to continue reading…

Cardiology Goes Better With Coke

At the bottom of this post I’ve reprinted an email cardiologists are receiving from the American College of Cardiology. See the bottom of the message for the disclosure that Coca Cola is paying for this educational program. I don’t have much to say about this though I wonder what the faculty of this program will…

Click here to continue reading…

Hypertension And Cholesterol Guidelines Delayed Again As NHLBI Gets Out Of The Guidelines Business

NHLBI Director Dr. Gary Gibbons

The National Heart, Lung, and Blood Institute (NHLBI) will no longer issue guidelines, including the much-delayed and much-anticipated hypertension (JNC 8) and cholesterol (ATP IV) guidelines. Instead, the NHLBI will perform systematic evidence reviews that other organizations, including the American Heart Association and the American College of Cardiology, will use as a resource for their own guidelines….

Click here to continue reading…

Spinning RECORD: Battle Over Rosiglitazone Heats Up Two Weeks Before Crucial FDA Meeting

Battle lines are being drawn two weeks before a highly unusual two-day FDA advisory committee meeting to discuss the contentious diabetes drug rosiglitazone (Avandia, GlaxoSmithKline). This will be the second time an FDA panel has wrestled with the fate of the drug and expectations have been that the discussion will once again be heated. But at…

Click here to continue reading…

Actelion Executive To Head American College of Cardiology

Shalom Jacobovitz

Shalom “Shal” Jacobovitz will be the new chief executive officer of the American College of Cardiology, the ACC announced today. Jacobovitz is currently the president of the US division of Actelion Pharmaceuticals, best known for its pulmonary hypertension drugs. Click here to read the complete story on Forbes.  …

Click here to continue reading…

The PREVAIL Fail Revisited: Spinning The Truth

The biggest story at the American College of Cardiology meeting last week was the missing story. As reported here and just about everywhere else, the PREVAIL trial, probably the most-anticipated late-breaker of the meeting, was pulled from the program at the last minute by the ACC leadership after Boston Scientific broke the embargo by issuing…

Click here to continue reading…

Following An Embargo Break PREVAIL Trial Won’t Be Presented At ACC

UPDATED–The already complicated story behind the PREVAIL trial, which was designed to confirm the safety and efficacy of the Watchman left atrial appendage closure device, just got even more complicated. This morning, after the trial’s sponsor, Boston Scientific, prematurely distributed to investors a press release summarizing the results of the trial, the ACC announced that…

Click here to continue reading…

Trials Of Niacin And Atrial Fibrillation Device Will Headline American College Of Cardiology Program

ACC.13 logo

Two big trials will highlight this year’s American College of Cardiology meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific‘s long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation. Second is  the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. Read my…

Click here to continue reading…